As a second part of a recent video I did that introduces the concept of a mixed response in lung cancer (or many other cancers) and how we might...
The question of whether and how to use blood tests, and particularly serum tumor markers, to monitor the status of a lung cancer has come up often...
Here's a brief video that explains my approach to a so-called "mixed response" to treatment for a lung cancer. [powerpress] There isn't a formal...
Here's a video I just did in response to my recent spate of molecular marker studies I've sent in the last 4-6 weeks that have come back with quite a...
We'll kick off our monthly live webinar series, co-sponsored by GRACE along with LUNGevity Foundation, with our annual "Highlights in Lung Cancer"...
Dr. Nate Pennell from Cleveland Clinic reviews the LUME Lung-1 trial presented by Reck at ASCO 2013, of Taxotere with or without nintedanib (BIBF-1120), an anti-angiogenic multikinase inhibitor, in advanced NSCLC.
[powerpress]
Dr. Heather Wakelee, from Stanford University, describes which molecular markers she seeks for NSCLC patients.
[powerpress]
Dr. Mary Pinder reviews promising studies from ASCO 2013 on second gen. ALK inhibitors LDK-378, CH5424802, and AP26113 in patients with ALK-positive advanced NSCLC, including impressive activity in crizotinib-refractory patients and those with brain mets.
[powerpress]
Drs. Mary Pinder, Nate Pennell, and Jack West discuss promising work on immune checkpoint inhibitors such as MPPL-3280A, an anti-PDL1 immune-based therapy, and anti-PD1 therapy nivolumab, in advanced NSCLC.
[powerpress]
Drs. Mary Pinder, Nate Pennell, and Jack West discuss the results presented at ASCO 2013 of the GALAXY-1 trial of the HSP90 inhibitor ganetespib combined with Taxotere (docetaxel) as second line therapy for advanced NSCLC.
[powerpress]
Dr. Karen Kelly, of the University of California, Davis, gives her view on more widespread availability of new mutation tests.
[powerpress]
Drs. Nate Pennell, Mary Pinder, and Jack West review the results presented at ASCO 2013 from the POINTBREAK trial of maintenance therapy with the ECOG 4599 regimen vs. carboplatin/Alimta (pemetrexed)/Avastin (bevacizumab) followed by Alimta/Avastin maint.
[powerpress]
Drs. Nate Pennell, Mary Pinder, and Jack West review the results presented at ASCO 2013 from the PRONOUNCE trial of the ECOG 4599 trial regimen compared with carboplatin/Alimta (pemetrexed) followed by maintenance Alimta.
[powerpress]
Dr. Phil Bonomi, from Rush University, describes which patients with advanced non-small cell lung cancer he would recommend getting a repeat biopsy to obtain sufficient tissue to perform molecular marker testing.
[powerpress]
Drs. Mary Pinder, Nate Pennell, and Jack West review results from the PROSE trial presented at ASCO 2013, testing the predictive value of the Veristrat test of serum proteomics to assess the potential value of erlotinib (Tarceva) in advanced NSCLC.
[powerpress]
Welcome to the new CancerGRACE.org! Explore our fresh look and improved features—take a quick tour to see what’s new.